Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus

Figures & data

Table 1 Summary of the AMIGO trials

Trial	No. of participants	Exenatide + [drug] versus placebo + [drug]	Effect of 5 μg exenatide on HbA1c	Effect of 10 μg exenatide on HbA1c	Effect of placebo on HbA1c
AMIGO-1^Citation20	336	Metformin	0.4% reduction	0.8% reduction	0.1% increase (P < 0.002 vs placebo for both exenatide groups)
AMIGO-2^Citation19	377	Sulphonylurea	0.5% reduction	0.9% reduction	0.1% increase (P < 0.001 vs placebo for both exenatide groups)
AMIGO-3^Citation21	733	Metformin and sulphonylurea	0.6% reduction	0.8% reduction	0.2% increase (P < 0.001 vs placebo for both exenatide groups)

DeFronzo RA Ratner RE Han J Kim DD Fineman MS Baron AD Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Diabetes Care 2005 28 1092 1100 15855572

 PubMed Web of Science ®Google Scholar

Buse JB Henry RR Han J Kim DD Fineman MS Baron AD for Exenatide-113 Clinical Study Group Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes Diabetes Care 2004 27 2628 2635 15504997

 PubMed Web of Science ®Google Scholar

Kendall DM Riddle MC Rosenstock J Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea Diabetes Care 2005 28 1083 1091 15855571

 PubMed Web of Science ®Google Scholar